At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMND Clearmind Medicine, Inc.
Post-Market Trading 11-26 19:58:29 EST
1.33
+0.00
0.00%
盘后1.35
+0.02+1.50%
18:42 EST
High1.35
Low1.32
Vol13.75K
Open1.33
D1 Closing1.33
Amplitude2.26%
Mkt Cap5.39M
Tradable Cap4.27M
Total Shares4.06M
T/O18.37K
T/O Rate0.43%
Tradable Shares3.21M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Massachusetts psychedelics legalization initiative poised to fail
Clearmind Medicine and Yissum Expand Collaboration With International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.